Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Carlos Alberto Gomez-Roca, Valentina Boni, Victor Moreno, John Charles Morris, Jean-Pierre Delord, Emiliano Calvo, Kyriakos P. Papadopoulos, Olivier Rixe, Patrick Cohen, Alexia Tellier, Samira Ziti-Ljajic, Anthony W. Tolcher
Title A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).
Journal J Clin Oncol
Vol
Issue
Date
URL http://meetinglibrary.asco.org/record/125293/abstract
Abstract Text J Clin Oncol 34, 2016 (suppl; abstr 2511)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
SAR566658 SAR566658 is a monoclonal antibody against CA6 in conjugation with maytansinoid, which may deliver targeted cytotoxicity to MUC-1 over expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 2511).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable SAR566658 Phase I Actionable In a phase I trial, SAR566658 treatment resulted in complete response in 1% (1/114), partial response in 7% (8/114), and stable disease in 39% (44/114) of patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2511)). detail...